Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   МақолаCAR-T cell therapy researchJournal of Hematology & Oncology20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer

   Viktoria B. Poluektova, Svetlana N. Zuevskaya, Yarmatov Suvon +3

   МақолаCAR-T cell therapy researchClinical & Translational Oncology20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.008555